Actively Recruiting
Phase I Study of Increasing Doses of Nab-paclitaxel With Radiation Therapy for Stage III-IVa Nasopharyngeal Cancer
Led by Sun Yat-sen University · Updated on 2024-09-27
24
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying nasopharyngeal carcinoma NPC to find the maximum tolerated dose and the recommended phase II dose of nab-paclitaxel when given together with radiotherapy. This phase I clinical trial focuses on patients with stage III to IVa NPC, aiming to carefully observe how patients respond to different doses of nab-paclitaxel during treatment. All participants will receive nab-paclitaxel during radical radiotherapy following induction chemotherapy. The study gradually increases the doses from 180 mgm8 to 260 mgm8, monitoring patients closely throughout the treatment period to assess tolerance and side effects. Participants will be involved from the start of radiotherapy until two weeks after its completion. Researchers will track the maximum tolerated dose and recommend the best dose for future studies. Throughout the trial, patients will undergo regular assessments to monitor their response and safety during and after treatment.
CONDITIONS
Brief Title
Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma
Research Team
F
Fang-Yun Xie
P
Pu-Yun OuYang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here